CombiMatrix and Oklahoma State University Collaborate on Influenza A 'Bird Flu' Research Program.
Business Editors/Health/Medical Writers
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--March 26, 2004
Acacia Research Corporation (Nasdaq:CBMX)(Nasdaq:ACTG ACTG Acting
ACTG AIDS Clinical Trial Group
ACTG Actuating/Actuator ) announced today that Dr. Ulrich Melcher, Department of Biochemistry & Molecular Biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller and Dr. Alexander C. Lai, Department of Microbiology and Molecular Genetics molecular genetics
The branch of genetics that deals with hereditary transmission and variation on the molecular level. , from Oklahoma State University Oklahoma State University, at Stillwater; land-grant and state supported; coeducational; chartered 1890, opened 1891 as Oklahoma Agricultural and Mechanical College, renamed 1957. , will utilize CombiMatrix's 'Bird Flu' CustomArray(TM) devices to characterize influenza A influenza A
Influenza caused by infection with a strain of influenza virus type A.
influenza A Infectious disease An avian virus, especially of ducks–which in China live near the pig reservoir and 'vector'; viruses at the genomic level. One goal of this project is to speed the development of better identification and characterization methods for influenza viruses.
CombiMatrix's 'Bird Flu' arrays will be utilized by Drs. Melcher and Lai to study and characterize various strains of the human and avian flu viruses for rapid typing of a wide range of subtypes from H1 to H15 and N1 to N8. Drs. Melcher and Lai's work in the characterization of influenza virus strains by microarrays was recently published in the Journal of Clinical Microbiology The Journal of Clinical Microbiology is an academic journal published by the American Society for Microbiology. The title is commonly abbreviated JCM and the ISSN is 0095-1137 for the print version, and 1098-660X for the electronic version. .
"The CombiMatrix Influenza A arrays will help to accelerate our research in identifying and characterizing the key differences in the avian flu strains. The data from these arrays will provide important information which will enable us to advance our research efforts," said Dr. Melcher. "These arrays should allow us to better understand the strains of Avian Flu that are most dangerous to humans and help us move towards development of diagnostics and therapeutics."
"CombiMatrix's 'Bird Flu' array and its proprietary content joins a growing list of viral arrays being developed and used by researchers to study emerging diseases," said Dr. Amit Kumar, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CombiMatrix. "Using our CustomArray(TM) line of products, researchers can design arrays to include any sequence from multiple pathogens all on the same chip. Rapid redesign of our arrays provides researchers with the necessary tools to study emerging infectious diseases. This program is synergistic with our work with St. Jude Children's Research Hospital St. Jude Children's Research Hospital, founded in 1962, is a leading pediatric treatment and research facility focused on children's catastrophic diseases. It is located in Memphis, Tennessee.
In 1996, Peter Doherty, Ph.D., of St. ."
ABOUT ACACIA RESEARCH CORPORATION
Acacia Research Corporation comprises two operating groups: Acacia Technologies Group and CombiMatrix Group.
The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications including DNA DNA: see nucleic acid.
or deoxyribonucleic acid
One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. synthesis/diagnostics, siRNA synthesis, drug discovery, and immunochemical im·mu·no·chem·is·try
The chemistry of immunologic phenomena, as of antigen-antibody reactions.
im detection. CombiMatrix provides DNA arrays to researchers under the CustomArray(TM) brand. CombiMatrix's Express Track(sm) drug discovery program is a systems biology approach, using its technology, to target common viral diseases with siRNA compounds.
The Acacia Technologies Group develops, acquires, and licenses patented technologies. Acacia's DMT See DSL. technology, which is supported by 5 U.S. and 31 foreign patents, relates to audio and audio/video transmission and receiving systems commonly known as audio-on-demand, video-on-demand, and audio/video streaming, and is used for distributing digital content via several means including Internet, cable, satellite and wireless systems.
Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.
Information about the Acacia Technologies Group and the CombiMatrix Group is available at www.acaciaresearch.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.